Table 1 Summary of typical cell viability studies
From: A review on cell damage, viability, and functionality during 3D bioprinting
Method | Bioink | Application | Cell viability | References |
|---|---|---|---|---|
Inkjet-based bioprinting | PEGDMA, human chondrocytes | Cartilage-like constructs | 89% | [139] |
Sodium alginate, 3T3 fibroblasts | Zigzag tubes | 82% | [140] | |
Sodium alginate, 3T3 fibroblasts | Vascular-like constructs | > 90% after 1 d | [141] | |
PEG/peptide, hMSCs | Cartilage-like constructs | 89% | [86] | |
Extrusion-based bioprinting | Nanofibrillated cellulose, alginate, hNCs | Aricular constructs | 70% | [44] |
Alginate sulfate, nanocellulose, chondrocytes | Miniature ears | > 85% at day 14 | [142] | |
Polyurethane solutions and NSCs | Nerve-like constructs | > 50% after 1 d | [143] | |
Alginate, fibroblasts, smooth muscle cells | Vascular-like constructs | > 91% after 7 d | [9] | |
Laser-assisted bioprinting | Alginate, 3T3 fibroblasts | 3D constructs | > 90% | [144] |
HUVECs, biopaper | Osseous constructs | 92.4% | [72] | |
3T3 fibroblasts | 3D constructs | > 93.5% | [145] | |
Hyaluronic acid, hiPSCs | 3D constructs | > 94% with control effect | [146] | |
Stereolithography-based bioprinting | GelMA, PEGDA, EY, 3T3 fibroblasts | 3D structure | 85% for at least 5 d | [21] |
GelMA, EY, 3T3 fibroblasts | 3D structure | 91.5% | [124] | |
GelMA, HUVECs, C3H/10T1/2 cells | Prevascularized tissues | > 85% | [147] | |
GelMA, LAP, mBMSCs | Native-like tissues | 95% | [148] |